Drug Trial Radar · NCT00630539
A Clinical Study to Evaluate the Efficacy and Safety of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women
Last checked: Nov 20, 2026Latest source record: Jun 28, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
126
Actual
Start
Aug 2007
Primary completion
Jan 2008
Study completion Feb 2008
Sponsor
- Lead sponsor
- ShionogiIndustry
- Sponsor type
- Industry
- Collaborators
- Hormos Medical; QuatRx Pharmaceuticals
- First posted
- Mar 7, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the efficacy, safety and tolerability of Ospemifene 5 mg, 15 mg, and 30 mg in the treatment of VVA in postmenopausal women to find the minimum effective dose below the lowest dose of 30 mg tested earlier in Phase II.
Conditions
- Atrophy
- Vaginal Diseases
Interventions
PlaceboDrug
1 tablet per day, orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
Ospemifene 5 mgDrug
1 tablet of ospemifene 5 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
Ospemifene 15 mgDrug
1 tablet of ospemifene 15 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
Ospemifene 30 mgDrug
1 tablet of ospemifene 30 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Percentage of Parabasal Cells in the Maturation Index of the Vaginal SmearTime frame: 12 weeks
- Mean Change From Baseline in Percentage of Superficial Cells in Maturation Index of the Vaginal SmearTime frame: 12 weeks
- Mean Change From Baseline in Vaginal pHTime frame: 12 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.